These reductions are comparable to those observed with tamoxifen, a commonly prescribed therapy, but were achieved at much lower doses of (Z)-endoxifen, offering improved tolerability. Both doses ...

334 patent at Title. The ’334 patent explains that endoxifen is an active metabolite of a drug known as tamoxifen. Id., 2:36-38. “Tamoxifen is a selective estrogen receptor modulator that is ...

(Z)-endoxifen appears to deliver similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with standard treatments, like tamoxifen.

(Z)-endoxifen appears to deliver similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with standard treatments, like tamoxifen ...

The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. Receive News & Ratings for ...

Whether increasing the dose of tamoxifen would improve efficacy is not known, nor whether using another form of endocrine therapy such as ovarian suppression with or without an aromatase inhibitor ...

Expert Rev Mol Diagn. 2013;13(4):349-65.